Neurocrine Biosciences (NBIX) Competitors $120.05 +3.94 (+3.40%) As of 02:04 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends NBIX vs. ALNY, BIIB, UTHR, INCY, BMRN, EXEL, EXAS, RGEN, HALO, and MDGLShould you be buying Neurocrine Biosciences stock or one of its competitors? The main competitors of Neurocrine Biosciences include Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), United Therapeutics (UTHR), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Exelixis (EXEL), Exact Sciences (EXAS), Repligen (RGEN), Halozyme Therapeutics (HALO), and Madrigal Pharmaceuticals (MDGL). These companies are all part of the "biotechnology" industry. Neurocrine Biosciences vs. Alnylam Pharmaceuticals Biogen United Therapeutics Incyte BioMarin Pharmaceutical Exelixis Exact Sciences Repligen Halozyme Therapeutics Madrigal Pharmaceuticals Alnylam Pharmaceuticals (NASDAQ:ALNY) and Neurocrine Biosciences (NASDAQ:NBIX) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, media sentiment, risk, institutional ownership, valuation, dividends, earnings, community ranking and analyst recommendations. Is ALNY or NBIX more profitable? Neurocrine Biosciences has a net margin of 14.49% compared to Alnylam Pharmaceuticals' net margin of -12.37%. Neurocrine Biosciences' return on equity of 13.38% beat Alnylam Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Alnylam Pharmaceuticals-12.37% N/A -6.83% Neurocrine Biosciences 14.49%13.38%9.73% Do analysts rate ALNY or NBIX? Alnylam Pharmaceuticals currently has a consensus target price of $299.48, suggesting a potential upside of 17.54%. Neurocrine Biosciences has a consensus target price of $166.90, suggesting a potential upside of 37.29%. Given Neurocrine Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Neurocrine Biosciences is more favorable than Alnylam Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alnylam Pharmaceuticals 1 Sell rating(s) 5 Hold rating(s) 19 Buy rating(s) 0 Strong Buy rating(s) 2.72Neurocrine Biosciences 0 Sell rating(s) 5 Hold rating(s) 17 Buy rating(s) 1 Strong Buy rating(s) 2.83 Does the media refer more to ALNY or NBIX? In the previous week, Alnylam Pharmaceuticals had 5 more articles in the media than Neurocrine Biosciences. MarketBeat recorded 37 mentions for Alnylam Pharmaceuticals and 32 mentions for Neurocrine Biosciences. Neurocrine Biosciences' average media sentiment score of 0.56 beat Alnylam Pharmaceuticals' score of 0.52 indicating that Neurocrine Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alnylam Pharmaceuticals 19 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Neurocrine Biosciences 13 Very Positive mention(s) 4 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive Which has better earnings and valuation, ALNY or NBIX? Neurocrine Biosciences has higher revenue and earnings than Alnylam Pharmaceuticals. Alnylam Pharmaceuticals is trading at a lower price-to-earnings ratio than Neurocrine Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlnylam Pharmaceuticals$2.25B14.67-$278.16M-$2.17-117.41Neurocrine Biosciences$2.36B5.15$341.30M$3.2936.95 Does the MarketBeat Community prefer ALNY or NBIX? Alnylam Pharmaceuticals received 116 more outperform votes than Neurocrine Biosciences when rated by MarketBeat users. However, 77.45% of users gave Neurocrine Biosciences an outperform vote while only 76.20% of users gave Alnylam Pharmaceuticals an outperform vote. CompanyUnderperformOutperformAlnylam PharmaceuticalsOutperform Votes114376.20% Underperform Votes35723.80% Neurocrine BiosciencesOutperform Votes102777.45% Underperform Votes29922.55% Which has more risk & volatility, ALNY or NBIX? Alnylam Pharmaceuticals has a beta of 0.35, meaning that its stock price is 65% less volatile than the S&P 500. Comparatively, Neurocrine Biosciences has a beta of 0.33, meaning that its stock price is 67% less volatile than the S&P 500. Do insiders and institutionals have more ownership in ALNY or NBIX? 93.0% of Alnylam Pharmaceuticals shares are held by institutional investors. Comparatively, 92.6% of Neurocrine Biosciences shares are held by institutional investors. 1.5% of Alnylam Pharmaceuticals shares are held by insiders. Comparatively, 4.3% of Neurocrine Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. SummaryNeurocrine Biosciences beats Alnylam Pharmaceuticals on 13 of the 19 factors compared between the two stocks. Get Neurocrine Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for NBIX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NBIX vs. The Competition Export to ExcelMetricNeurocrine BiosciencesBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$11.39B$3.09B$5.84B$9.20BDividend YieldN/A1.57%4.78%3.85%P/E Ratio35.2910.0116.3214.14Price / Sales5.15342.88461.0479.70Price / Cash33.81183.5344.0437.47Price / Book4.683.637.794.78Net Income$341.30M-$71.72M$3.18B$245.88M7 Day Performance5.70%-0.24%-0.52%-0.90%1 Month Performance-16.66%2.30%1.80%-0.52%1 Year Performance-6.95%-9.30%18.90%16.50% Neurocrine Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NBIXNeurocrine Biosciences4.9783 of 5 stars$120.05+3.4%$166.90+39.0%-12.5%$11.96B$2.36B36.471,800Analyst DowngradeAnalyst RevisionGap UpALNYAlnylam Pharmaceuticals4.5539 of 5 stars$256.45-3.2%$299.43+16.8%+68.7%$33.08B$1.83B-97.882,100Analyst ForecastInsider TradeBIIBBiogen4.7769 of 5 stars$137.33-0.8%$211.96+54.3%-37.5%$20.01B$9.84B12.417,570Analyst ForecastUTHRUnited Therapeutics4.4129 of 5 stars$370.58+0.0%$382.08+3.1%+71.5%$16.55B$2.33B16.271,168Insider TradeINCYIncyte4.5814 of 5 stars$70.42+0.6%$75.59+7.3%+21.4%$13.57B$3.70B503.042,524BMRNBioMarin Pharmaceutical4.9364 of 5 stars$64.85+0.7%$94.20+45.3%-22.5%$12.36B$2.42B38.833,401Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageEXELExelixis4.6803 of 5 stars$35.00+1.5%$37.24+6.4%+70.1%$10.00B$1.83B22.441,310Analyst UpgradeInsider TradeGap UpEXASExact Sciences4.671 of 5 stars$49.31-2.5%$72.76+47.6%-21.1%$9.13B$2.50B-42.146,600Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageRGENRepligen4.3262 of 5 stars$146.92+0.5%$182.91+24.5%-18.6%$8.23B$638.76M-397.071,783Earnings ReportAnalyst ForecastNews CoverageHALOHalozyme Therapeutics4.5001 of 5 stars$58.29-0.5%$60.89+4.5%+59.6%$7.42B$829.25M19.30390Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageMDGLMadrigal Pharmaceuticals3.3531 of 5 stars$337.20-4.1%$351.67+4.3%+52.8%$7.35BN/A-13.4490 Related Companies and Tools Related Companies Alnylam Pharmaceuticals Competitors Biogen Competitors United Therapeutics Competitors Incyte Competitors BioMarin Pharmaceutical Competitors Exelixis Competitors Exact Sciences Competitors Repligen Competitors Halozyme Therapeutics Competitors Madrigal Pharmaceuticals Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:NBIX) was last updated on 2/21/2025 by MarketBeat.com Staff From Our PartnersNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredThree new patents reveal Elon and Trump’s secret “Project America”Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR!...Timothy Sykes | SponsoredBITCOINDid you miss out on the 1000%+ gains of Bitcoin over the past 5 years? If so, you don't want to miss this.....Awesomely, LLC | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neurocrine Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neurocrine Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
